FDA approval

Dark cinematic banner with Eli Lilly logo and Foundayo oral GLP-1 FDA approval headline on molecular data background

Lilly’s Foundayo FDA Approval Resets the GLP-1 Commercial Playbook

AI in Biotech Commercial Operations /

The FDA approved Foundayo (orforglipron) by Eli Lilly on April 1 2026 as a once-daily oral GLP-1 for obesity. With no food restrictions, small-molecule manufacturing, $25 monthly pricing with insurance, and a DTC launch through LillyDirect, Foundayo resets access and distribution assumptions across the entire GLP-1 market. Analysts forecast $14.79 billion in sales by 2030.

Lilly’s Foundayo FDA Approval Resets the GLP-1 Commercial Playbook Read More »

Dark cinematic banner with Kite Pharma logo and Tecartus FDA full approval headline on molecular background

FDA Converts Tecartus to Full Approval in Relapsed Mantle Cell Lymphoma

AI in Regulatory Intelligence /

The FDA granted full approval to Tecartus on April 3 2026 for adult patients with relapsed or refractory mantle cell lymphoma based on ZUMA-2 cohort 3 data showing a 91% response rate in BTK-naive patients. Full approval removes payer friction and expands the eligible patient population but increases pressure on CAR-T manufacturing capacity and treatment centre readiness.

FDA Converts Tecartus to Full Approval in Relapsed Mantle Cell Lymphoma Read More »